loratadine + loratadine + loratadine
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Perennial Allergic Rhinitis
Conditions
Perennial Allergic Rhinitis
Trial Timeline
Jun 1, 2008 → Dec 1, 2008
NCT ID
NCT00730912About loratadine + loratadine + loratadine
loratadine + loratadine + loratadine is a approved stage product being developed by Merck for Perennial Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00730912. Target conditions include Perennial Allergic Rhinitis.
What happened to similar drugs?
13 of 20 similar drugs in Perennial Allergic Rhinitis were approved
Approved (13) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00730912 | Approved | Completed |
Competing Products
20 competing products in Perennial Allergic Rhinitis